Letarouilly JG, Flachaire B, Labadie C, et al. - This study was undertaken to investigate the characteristics of patients (pts) with psoriatic arthritis (PsA) treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA. Researchers conducted a retrospective, national, multicentre cohort study including pts with PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) initiating UST or SEK with a follow-up ≥ 6 months between January 2011 and April 2019. They enrolled a sum of 406 pts: 245 with UST and 161 with SEK. The persistence of SEK was higher than that of UST in PsA in this first study comparing UST and SEK. This variation was only found in association with MTX in subgroup analysis.